Obviously the purpose of the GALA trial was to show that the thrice-weekly 40mg formulation's efficacy and safety are in the same ballpark as the 'known' profile of regular daily Copaxone, with emphasis on the convenience benefit. That's what they need to file. Converting patients is harder but as long as there's no generic version...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.